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INTRODUCTION 
Renal   dysfunction   is   a   frequent   complication  in  cirrhotics   and  
this  combination   has  got  a  significant   morbidity  and  mortality.  Both  
liver  and  kidney   disease  can  occur  simultaneously  or  a  primary  liver  
disease  can  lead  to  secondary  abnormalities  in  kidney  function(1)  
  Decreased   renal  function   in  patients   with  cirrhosis  is  usually    
functional  without  any   structural  abnormality   and  occurs   gradually   over  
a  period  of  time   and  has   a   negative   impact  on  the   prognosis   of   
patients(2,3).   
The   incidence   of   renal  failure  in  advanced  chronic   liver   disease  
ranges   from  15%  to  50%(4).Patients  with  cirrhosis  have  circulatory   
dysfunction   and  diminished  effective  arterial  volume   leading  to   acute     
renal   dysfunction  in   these   patients.   This  acute  kidney  injury   may  be  
spontaneous  or  precipitated  by    infection , use  of  nephrotoxic   drugs , 
blood  loss  or  gastrointestinal   fluid  losses. 
    The   accurate  assessment  of  renal  function  is  these  patients  is  
proving  to  be  difficult   due  to  excessive   dependence   on   the   plasma  
creatinine  whose  levels   are  dependent  on  various  factors  like  the  severity  
of  chronic  liver  disease , malnutrition  and  elevated  bilirubin  levels    which  
interferes  with  the  estimation   of  serum   creatinine. 
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Conventional  biomarkers  like  blood  urea , plasma  creatinine  and  
urine  markers   are  non specific   and  insensitive    for  the   detecting  an  
acute decrease  in  renal  function    in  these  patients.  Newer   biomarkers   for  
detecting  renal  injury   are  being  evaluated  in  various  studies.  These    
include  both   serum   and  urine   biomarkers   namely   serum  neutrophil  
gelatinase  associated   lipocalin  (sNGAL )  and  cystatin  C.  Urinary  
biomarkers  include    kidney  injury  molecule (  KIM-1 ),  NGAL   (u NGAL )  
and   interleukin  -18  (  IL-18  )(5). 
It  is  imperative  to   detect   the  onset,  severity  and  progression  of  
renal   dysfunction  in   cirrhotics  as  this   has   got    a   major  impact  on  the  
survival   of  these  patients   and  is  one    of  the  major  risk  condition  
affecting  the  prognosis  in  patients  undergoing  liver  transplantation  . 
Patients  with  pre  transplant    renal   dysfunction  are  prone   to   
develop   complications  than   those  without  renal  failure. 
This  emphasises  the  need  for  the  earlier  detection  of   renal  
dysfunction in  cirrhotics    for  optimal  management   of  these  patients.  This  
has prompted  the  evaluation  of  several  biomarkers  of  renal  injury  like      
kidney   injury  molecule,  serum  and  urine   NGAL   and   cystatin  C   as  
markers  of  renal  injury in  these  patients. Of  these  biomarkers    Cystatin  C  
has  been  studied  the  most  in  cirrhotics  and  it  has  been  proved   to  be  a  
superior  marker  to  serum  creatinine   in  this  subgroup  of  patients. 
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AIMS 
 
1. To   evaluate  the  diagnostic  accuracy  of  plasma  creatinine   and   
creatinine  based  formulas  in  assessing  renal  functions  in  patients  with  
chronic  liver  disease 
 
2. To  assess  the  diagnostic  accuracy  of  cystatin C and  cystatin C   based  
equations  in  assessing  renal  functions  in  chronic  liver  disease  patients. 
 
 
3. To  find  out   whether  etiology  of  chronic  liver  disease  has  an  impact  
on  renal  function  in  these  patients. 
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REVIEW  OF LITERATURE 
HISTORY : 
Frerich   and   Flint    reported   two  cases  of  chronic   liver  disease   
with   renal   dysfunction  in  the  late  nineteenth   century(6).  They  described  
the  occurrence  of  oliguria  in  cirrhotics  in  the  absence   of  structural  renal  
disease  and  proteinuria  in  these  patients.   Helwig  and  Schutz  coined  the  
term  “ Hepato renal  syndrome”  in  1932. 
But  it  was   Sherlock, Popper  and  Vessin  in  1950 s  who  elaborated  
the  functional   nature  of  this  syndrome  and  the  occurrence  of  co existing  
systemic  circulatory  disturbances  and   its  adverse  impact  on  prognosis  in  
the  cirrhotics.  
  Further   studies  undertaken  during  the  last  two  decades  have  shown  
that  intense  systemic  arterial  vasodilation  in cirrhotics  led  to  severe  renal  
vasoconstriction  which  predisposed  these  patients  to  develop  acute  renal  
dysfunction, the  most   disastrous  complication  being  the  development  of  
Hepatorenal  syndrome. 
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  The  vicious  cycle  of  renal  failure  starts  with  systemic  circulatory  
disturbances .  There  is  hyperdynamic  circulation  due  to  portal  hypertension  
which  results  from  scarring  and  fibrosis  and  architectural  distortion of  
liver. Increased  cardiac  output  and  dilatation  of  peripheral  vasculature   is 
due  to  the  release  of  endogenous   compounds   like   nitric  oxide(7)  which  
are    shunted  from  regional  splanchnic  to  systemic  circulation. 
Adrenomedullin,  cannabinoids   and  carbon   monoxide  are  other  
vasodilators  causing   systemic  arterial  vasodilatation  leading  to  impaired  
effective   arterial  blood  volume . Splanchnic  circulation  undergoes  
predominant  vasodilatation  where as  renal  vessels  undergo  relative  
vasoconstriction.(8) 
The  diminished  effective  arterial  volume  simulates  a   state  of  
relative  hypovolemia   which  leads  to  activation  of  compensatory  
mechanisms  like the   arginine   vasopressin,   sympathetic  nervous  system  
and  RAAS  (9,10)   which  try  to  conserve  sodium  levels  in the  body   . 
Excessive  sodium  retention  leads  to  fluid  accumulation   and  ascites  in  
these  patients. Dilutional   hyponatremia  is  a  common  complication  of  fluid  
retention  in   patients  in  advanced  stages  of  liver  disease.  Severe   and  
persistent  activation  of  all   these   compensatory   mechanisms    leads  to   
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constriction  of  extrasplanchnic  vasculature  in  kidney  leading  to  
hepatorenal  syndrome  and  in  brain  resulting   in  encephalopathy  in  these   
patients    leading   to  multiorgan  dysfunction .Intrarenal  imbalance  of  
vasodilatory  compounds  like  prostaglandins, kallikreins  and  vasoconstrictors     
like  endothelins(11 are  postulated to be  responsible  for  renal  vasoconstriction   
Renal  arterial  flow  is  maintained  in  the  normal  range   during  the  
earlier  stages  of  hepatic  disease  and   this    may  deteriorate  suddenly  if  a 
‘second  hit’  occurs  which  may  be  in  the  form  of  gastrointestinal  fluid  
losses  leading  to  true  hypovolemia  in  cirrhotics   who  are  already   at   risk  
of  developing  renal  failure.  Persistent  vasoconstriction   leads  to  decrease  
in  filtration  of  glomerular  surface  area  resulting  in  ischemic  acute  tubular  
necrosis  in these  patients.   
Acute  renal  failure   can  also  be  due  to    iatrogenic   causes  like  use   
of  nephrotoxic   drugs  like  aminoglycosides,  excessive   fluid  loss  due  to  
large  volume  and  repeated  abdominal  paracentesis,  blood  loss .  Renal  
dysfunction  precipitated  by  infection  usually  resolves  when  the  infection  
is  being  treated.  
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 CAUSES  OF  RENAL  FAILURE  IN  CIRRHOSIS : 
In  hospitalized  patients  with    cirrhosis  pre renal  azotemia  is  the  
predominant   cause  of  acute  renal  failure  contributing  to  about  50 % .  It  
is  followed  by  acute  tubular  necrosis  (30%) , hepatorenal syndrome  (17%)  
and  post  renal  failure  (<1% )(12,13)    
PRERENAL: 
The   persisting  state  of  relative  hypovolemia   can   be    exacerbated  
by   actual  fluid  loss   like  gastrointestinal  fluid  losses  due  to  excessive  
vomiting  and  diarrhoea,  blood  loss  due  to   variceal  bleeding  which  occurs  
in  portal  hypertension or  coagulation  abnormalities  which  is  one  of  the  
common  complications  in  advanced  decompensated  liver  disease  or  peptic   
ulcers  causing  a  sudden  drop  in  intravascular  volume  thus  leading  to  
prerenal  azotemia. 
Iatrogenic  causes  of  prerenal  azotemia  include  excessive  use  of  
diuretics, repeated  and  large   volume  abdominal  paracentesis  in  the   
absence  of  adequate  intravascular   volume  replacement. The  use  of  non  
steroidal  anti inflammatory  drugs  can  exacerbate   renal  injury  due  to  
reduction  of    glomerular   filtration   pressure   which  initially  results  in  
prerenal  azotemia  but  can  progress  to  ischemic  tubular  necrosis  if  the  
injury  persists. 
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Dimnished  blood  flow  results  in   decreased  supply    of  sodium  to  
the  macula  densa   resulting  in  activation  of    RAAS  leading   to   ascites  
and  fluid  retention.  Presence  of   refractory  and  tense  ascites  can  further       
impair  renal  perfusion  and  contribute  to  renal  injury. 
Also  cirrhotics  are  more  prone  for  developing  spontaneous  bacterial  
peritonitis  because  of  the  low  opsonizing   capacity  due  to   diminished  
complement  activity. This occurs  more  when  the   total  protein  content  of  
the  ascitic   fluid  is  less  than  one  gram/ decilitre. 
  The  most  common  cause  of  spontaneous  bacterial  peritonitis  is  the            
gram  negative   bacteria  which  translocate   from    the   gut   to  the  
peritoneal  cavity.   Here  they  cause  an  inflammatory  reaction  leadingto  the  
production  of  vaso active  cytokines  which  causes  circulatory dysfunction  
by  causing  vasodilation   in  systemic  circulation   and   thereby diminishing  
the  effective  arterial  circulation. 
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INTRINSIC  RENAL   FAILURE: 
Acute  tubular  necrosis is  the  predominant   cause  of  parenchymal  
renal  injury  in  chronic  liver  disease  patients  .It is  an  extended  spectrum  
of  pre renal  azotemia  (15,16).It  usually  follows  an  episode  of  hypovolemic  
shock   or  after  major  surgical  procedures  causing  volume  loss  in  these  
patients. Other  causes  of  intrinsic  renal  failure  include  the  use  of  
nephrotoxic  agents   like  aminoglycosides  or  radiocontrast  agents. 
The  decreased   effective  glomerular  filtration  pressure  if  prolonged , 
leads  to   dislodging   of  tubular  epithelial    cells  from  the  basement  
membrane      followed  by  occlusion  of  tubular  lumen  by  cast  cells  leading  
to  established  acute  renal  failure  in  these  patients. 
Acute  renal  failure  caused  by  drugs  and  toxins  are  usually  
tubulointerstitial    where  as  alcoholic  cirrhosis  has  been  shown  to  cause  
glomerular    involvement. 
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HEPATORENAL  SYNDROME: 
Hepatorenal  syndrome  is  defined  as  acute   or  subacute  functional  
renal  failure   occurring  in  patients  with  advanced  liver  failure  or  portal  
hypertension(17,18). 
The  estimated  yearly    incidence  of  hepatorenal  syndrome  in  
cirrhotics  with  ascites    is  about  08%  The  probability  of   developing  HRS  
is  18%  in  one  year  and  39%  at  five  years(19). Most of  these  patients   are  
in  advanced  stages    of    decompensated   liver  disease. 
The    decrease  in  effective  arterial  blood  volume and sustained  
excessive   renal  vaso constriction ,  abnormal  auto regulation  which  occurs  
in  advanced  stages  of  cirrhosis   along  with  increasing  severity   of   portal  
hypertension  and  abnormal  cardiac  function   together  play  a role  in  the  
development  of  hepatorenal  syndrome  in  these  patients.  
Various  compounds  have  been  implicated  in  the  pathogenesis  of  
development   of  hepatorenal  syndrome.  These  include  adenosine,                
natriuretic  peptides ,  nitric  oxide,   endothelins   and  endotoxins.  
  In decompensated  liver  disease ,  the  increased  production  of              
adenosine   due  to  tissue  hypoxia   triggers  a  hepatorenal   reflex  that             
further  leads  to  a  decrease   in  renal  blood   flow  due  to  activation                    
of  sympathetic  nervous  system. 
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  ANP  and  BNP  though  postulated  to   have  a  protective  effect  by 
suppressing   the  stimulation  of  renin,  are  raised    in    patients  with  
decompensated  chronic  liver  disease  thus  showing  the   presence  of  
increased  resistance  to  atrial  natriuretic  peptide  in  these   patients.  Nitric  
oxide  plays  an  important  role  in  causing  renal  injury  in  cirrhotics. It  
controls  the  arteriolar  tone  and  causes  splanchnic  vasodilation and   also  
reduces  renal  blood  flow  resulting  in  progressive  renal  injury.  
 Endothelins  are  powerful  vasoconstrictors  implicated   in  the  
pathogenesis   of  hepatorenal  syndrome.  They  are  produced  in  increased 
amounts  in  cirrhotics  . Intrarenal  imbalance  between  the  vasoconstrictors 
and  vasodilators  like  prostaglandins  affects  the  renal  arterial  blood  flow 
contributing  to  renal  injury. 
Endotoxins  are  produced  from  the  colonization  of  the  patient’s  gut            
with  bacteria  and   they  act  as  systemic  vasodilators.  Since  they  are  not  
degraded  by  the  reticuloendothelial  system  due  to  diminished  immune  
competence  seen  in  these  patients  they  are  present  in  considerable  
amounts    to  cause  splanchnic  and  systemic  arterial  vasodilation  thus   
affecting  the   renal  blood  flow. 
The  renal  autoregulation  curve  is  shifted  to  the  right  in  cirrhotic   
patients   making  them  more  vulnerable  to  the  development  of  renal  
failure(20).  
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Increased   portal  pressure is  associated  with  decreased    renal  blood  
flow   due  to  increased  sympathetic  activity  to  the  renal    vessels.  This  
Hepato renal  reflex  contributes  to  renal  failure  in  cirrhotics. 
The  presence  of  systemic  arterial  vasodilatation  in  advanced  
cirrhosis   leads  to  a  hyperdynamic  circulation  with  increased  heart  rate, 
high  cardiac  output    and  reduced  peripheral  vascular  resistance  . In  
addition  there  is  a  new  concept  termed  as  cirrhotic  cardiomyopathy  
consisting  of  myocardial  thickening,  diastolic  dysfunction  at  rest,  and   
systolic  dysfunction  under  conditions  of  stress. 
Because   of  these  factors  the  heart  is  unable  to  further  increase  its  
cardiac  output  in  periods  of  stress  like  sepsis, resulting  in  further  
compromise  of   renal  circulation  and  predisposition  to  the  development  of  
hepatorenal  syndrome.(21-24). 
Hepatorenal  syndrome  is  a  diagnosis  of  exclusion.    The   criteria   
for  diagnosis   of  heptorenal  syndrome   include  major  and  minor  criteria.  
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MAJOR  CRITERIA : 
1. Acute  or  Chronic  liver  disease  with  advanced  hepatic  failure  
and  portal  hypertension 
2.  Serum  creatinine  >1.5 mg/dl   or  CrCl  <40  ml/min 
3. Absence  of  treatment   with  nephrotoxic  drugs, shock, infection  
or  gastrointestinal  fluid  losses 
4. No  sustained  improvement  in renal  function  after diuretic 
withdrawal  and  volume  expansion  with  1gm/kg  of  albumin  
upto  a maximum  of  100  grams. 
5. Proteinuria  <  500  mg/dl  and  no  ultrasonographic  evidence  of  
parenchymal  renal  disease. 
MINOR  CRITERIA: 
1. Urine  volume <  500  ml/day 
 
2. Urine  sodium  <10  mEq/L 
 
3. Urine  osmolality  more  than  plasma  osmolality 
 
4. Urine  red  blood  cells < 50  per  high  power field 
 
5. Serum  sodium  concentration  <130 mEq/L 
 
 
All  the  major  criteria  are  essential  where as  minor   criteria   are  
supportive but   not  essential  for  diagnosis  of  Hepatorenal  syndrome. 
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The  classification  of  Hepato renal  syndrome  (25) proposed  by  
 INTERNATIONAL  ASCITES  CLUB  is  as   follows: 
Type  1:   Cirrhosis  with  rapidly  progressive  acute  renal  failure. 
Type  2:   Cirrhosis  with  subacute  renal  failure 
Type 3:    Cirrhosis  with  Type 1 or  Type  2  HRS   superimposed  on  chronic 
      kidney  disease  . 
Type 4:   Fulminant  liver  failure  with  Hepatorenal  syndrome 
 
Patients   present  with  increased  serum  creatinine  ,reduced   creatinine    
clearance   and  low  urine  output. 
 
TYPE 1  HEPATORENAL  SYNDROME: 
Type  1  HRS  is  characterized  by  a   rapidly  progressive  renal failure  
, defined  as  doubling  of  the  initial  serum  creatinine  to   a  level  >2.5 mg/dl  
in  less  than  two  weeks.  It  usually  develops  following  a  precipitating    
event  but  can  occur   spontaneously.  Patients  are   usually  very  ill  , with  
severe  jaundice  ,coagulopathy  and  liver  failure. 
Cardiac  and  adrenal   dysfunction  further  exacerbate  the   circulatory  
dysfunction  in  type  1  HRS.  Tachycardia  is  less  prominent  in  patients   
with   HRS. Adrenal  dysfunction   is  important  in  contributing  to  
hemodynamic   disturbances   in  relating  to  type 1  HRS  related  to  sepsis. 
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Excessive  use  of  diuretics, repeated  abdominal   paracentesis   without 
intravascular  volume      replacement   in  patients   with  refractory  ascites and   
blood  loss  from  gastrointestinal  tract   are  well  known  precipitants  of  type  
1 HRS. 
Other   triggers  are  conditions  that  worsen  the  arterial  vasodilation 
like  sepsis (26)    especially   spontaneous  bacterial peritonitis  or  surgical   
jaundice ,    as  the  bile  acids  act  as   vasodilators. If  left  untreated  the  
median  survival of  type  1   hepatorenal  syndrome  is  two   weeks(27) 
 
Type  2  HRS: 
It  is  characterized  by  moderate  renal  failure    with serum   creatinine 
between  1.5  to  2.5  mg/dl.  It    usually  evolves  over  weeks   to  months  , 
typically  in  patients  with  ascites   refractory  to  diuretic   therapy. 
Type  2  HRS   is  felt  to  be  an  extension  of  refractory  ascites  when  
hemodynamic  changes  worsen  over  time.  Patients  with  type  2  HRS are  
usually  less  critical  compared   with  those  with  type  1  HRS  with  a milder  
degree   jaundice  and  coagulopathy. 
Precipitating  factors   are    usually  absent  in  type  2  HRS  . But  many   
patients  with   type 2  HRS    progress   to   the  more  severe  type  1,  often 
because  of  a  precipitating  event. 
If  left  untreated  the  mortality  of   type  2  HRS   is  50%  at  six   
months. 
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Type  3  HRS: 
Cirrhotics    with  co existent  renal  disease  are  more   prone  to     
develop  hepato  renal  syndrome.  Several  studies have  shown  that   cirrhotics    
developing     hepatorenal  syndrome    already  have  a  co  existing   kidney   
disease(28,29). The  pre existing renal  disease  may  be  hypertensive  or  diabetic  
nephropathy  or  chronic glomerulonephritis. The  acute  renal  injury  may  be  
in  the  form of  acute  tubular  necrosis  or  others. These  patients   are  subjects 
for  combined  liver  kidney  transplant  and  further  studies  are  needed  to  
validate  this  strategy. 
 
Type  4  HRS: 
Patients   with   acute  liver  failure   sometimes  develop  refractory   
ascites   and   extremely  high     portal pressure   which  predisposes  them  to 
HRS.  But  the  data  about  type  3  and  type  4  HRS  has  not  been validated. 
The  work  up   should  consist  of  a  full  septic  work  up, including   
blood  cultures ,  chest  x  ray  ,urine  and  sputum  cultures, a  diagnostic 
paracentesis  to  exclude  spontaneous  bacterial  peritonitis  and swabbing   any 
possible  source  of  infection. 
An  urinalysis  to  assess  for  casts,  proteinuria  and  hematuria   should  
be  done  to   exclude  organic kidney disease. An  abdominal   ultrasound  
should  be  done  to  exclude  contracted  kidneys or  other    structural  
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abnormalities  of  kidneys  or  post  renal  failure  resulting  from  obstruction  to  
passage  of  urine  like  bladder  neck  obstruction. 
A  trial   of  diuretic  withdrawal  , together  with  intravascular volume   
replacement  can  replenish  the  effective  arterial  blood  volume. The  
intravascular  volume  replacement  is  albumin  at  a dose  of   1 gram per  
kilogram     body  weight   upto  a  maximum  of  100  grams  per  day. 
 
TREATMENT   OF    HEPATORENAL  SYNDROME: 
The  rationale   for  various  treatment    options   for    hepatorenal  
syndrome   include   improving   the  effective  arterial  blood  volume  through  
volume  expanders  and  reducing  the  extent  of  splanchnic  and  systemic  
arterial   vasodilation  through  vasoconstrictors.  Portal  hypertension   can  be  
treated  with  transjugular intrahepatic  porto  systemic  shunt.  MARS  is  one  
of  the  treatment  options  for  elimination  of  toxins  which  act  as  
vasodilators.   Treatment  of  liver  dysfunction   and  elimination  of  portal  
hypertension  is  through   liver transplantation. 
The  precipitating   source  of  HRS  must  be  removed in  the   form  of  
treatment  of  infection,  withdrawal  of  nephrotoxic  medications,  including    
diuretics  and  nonsteroidal   anti inflammatories. 
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Also  antihypertensive  agents  like    ACE     inhibitors   and   
angiotensin  II  antagonists  should  be  stopped     because  in  patients   with  
decompensated cirrhosis    RAAS  is  vital  to  the  maintenance  of    arterial  
pressure   and  GFR   in  the  face  of  marked  peripheral  vasodilatation. 
Inhibition  of  RAAS may  precipitate   hypotension  and  deterioration  of     
renal    function. 
Albumin  improves  the  effective  arterial  blood  volume  .The  
recommended  dose  is  20  to  40  grams  of  albumin  in  combination  with  
vasoconstrictors,  after  the  initial  dose  of  one  gram  per  kilogram  body  
weight  on  the  first  day.  Albumin  alone  appears  to  be  ineffective  in  the  
treatment  of  HRS(30,31) 
The  peritoneovenous  shunt  drains  ascitic   fluid  into  the internal  
jugular  vein, thus  achieving  sustained  central  volume  expansion. It has  
failed  to  demonstrate  any  survival  advantage  in  HRS  and  therefore  is no 
longer  used  because  of  significant  complications  such  as  coagulopathy, 
postoperative   sepsis  and  shunt  occlusion  (32,33). Also   PV  shunts are   no  
longer  in  production  leading  to  inexpertise  in  inserting  PV  shunts. 
Renal  vasodilators  like  low  dose  dopamine, prostaglandin E1 
analogues  like  misoprostol   or  endothelin  receptor  antagonists  have  no  
proven  efficacy  in  the  treatment  of  type  1  Hepatorenal  syndrome (34). 
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Systemic  vasoconstrictors  by  reducing  the  extent  of  systemic 
vasodilation,  lead  to  a  rise   in  the  systemic  arterial   blood  pressure, which 
in   turn   increases  the  renal   perfusion   pressure.  
Midodrine  is  an  alpha  agonist   which  raises  systemic  vascular 
resistance   and  renal   perfusion  pressure. A mean  arterial   pressure  of > 70  
mm  Hg  should  be  maintained. 
Octreotide  is  a  synthetic   analogue   of  somatostatin  which decreases   
splanchnic  circulation  which  is  given  by  intravenous   infusion or  
subcutaneously. 
Vasopressin  is  a  V1  receptor  agonist  which  causes   vasoconstriction   
of   systemic   and   splanchnic  circulation .  But  it  is  not  commonly  used 
because  of  ischemic  side  effects. 
Terlipressin  is   a  vasopressin  analogue  with  less  ischemic   side 
effects   and  improves  renal  function  better  than  vasopressin. 
Norepinephrine  is   an   alpha   and   beta   adrenergic     agonist  which    
causes  systemic   vasoconstriction.  It   has  no   significant ischemic  side  
effects. 
Isolated    case    reports  have  suggested   the  useof   N-acetylcysteine  
(NAC)  in   combination   with   systemic  vasoconstrictors   or  endothelin  
receptor  antagonists.  This  is  based  on a small   case  study  of  twelve  
patients   with  HRS   who  showed  an improvement   in  serum  creatinine   
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after  an  intravenous  infusion  of   NAC, but  it  is  not   standard  clinical  
practice  at  this  time(35,36). 
Transjugular     intrahepatic   shunt   is  a  prosthesis   that  bridges  an   
intrahepatic    branch   of  portal  vein  with  the  hepatic  radicle.  It  is  effective  
in  reducing  portal   pressure.  It  also  returns   a  significant part  of  the   
splanchnic   vascular   volume    into  the   systemic circulation . 
To date , there  are  no  controlled   studies  assessing   the efficacy  of  
TIPS   for  the   management  of  HRS.  An  improvement  in renal   function  
has  been  observed ,  but  this   improvement  falls   short of  normalization   of  
the  GFR.  However , in  one  study  where vasoconstrictor   therapy  was  
followed  by  TIPS  insertion,  TIPS  was  able to  normalize  renal  function   
over   the  course  of  12  months. The  overall survival  was   50%  (37,38). 
Albumin  dialysis  removes  albumin- bound  substances, such as  cytokines   
and  bile  acids  , which  are   also   systemic  vasodilators. Albumin dialysis   
can  filter  out   creatinine     and  artificially  reduces  the  serum creatinine  
without    changing    the  GFR.  It  can  create  a  false  sense of   improvement  
when  there  is  no  recovery  of  renal  function.  But  there is   not   enough  
data  to  accept  it  as  standard  of  care. 
Liver  transplantation  corrects  liver  dysfunction  and  eliminates  portal 
hypertension . Renal  function   improves  in  many  patients  after  
transplantation,  but  up  to  40%  of   patients  can  remain  dependent  on 
dialysis. 
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Liver  transplantation  is  the  treatment  of  choice  for  type 1 and  type  
2  HRS.(39). Intermittent   hemodialysis  has  been  used  as  a  short term  bridge  
to  liver  transplantation. However  ,there  is  no  evidence  that  it increases  
long  term  survival  without  transplantation. 
 
PREVENTION  OF  HEPATO  RENAL  SYNDROME: 
One  third  of  patients  with  patients  with  spontaneous bacterial   
peritonitis   will  develop  renal  impairment  despite  appropriate antibiotic  
therapy.  Patients  who  receive  albumin   in  addition   to antibiotics have  been  
shown  to  have  a  lower  incidence  of    renal  impairment  and  death   
compared  to  those  treated  with  antibiotics  alone.  Patients  in  this study  
received  intravenous  albumin  at  a  dose  of  1.5  gram  per  kilogram 
bodyweight  on  day  1, then  one  gram  per  kilogram  body  weight  on  day 
3(40). Although  antibiotics  alone  have  not  been  shown  to  directly reduce  the  
incidence   of  HRS , primary  prophylaxis  of  spontaneous  bacterial  
peritonitis  with  norfloxacin  reduces  the  incidence  of  SBP  by 28%  which    
itself  is  a  risk  factor  for  HRS. 
Removal  of  large  volume  (>5  liters)   of  fluid   may  precipitate 
circulatory   dysfunction  , which  can  induce  renal  failure  in  up to  20 %  of 
patients. Giving  albumin  at  a  dose  of  eight  grams   per  litre   of  ascetic 
fluid  removed  has  been  shown  to  reduce  the   incidence  of   renal  failure 
but  not  mortality.(41) 
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There  is  no  specific  measure  adopted   for  the  prevention of  type  2  
HRS  because     patients   usually  have  no  precipitating factors  for  
developing  this  variant  of  HRS. Treatment  of  refractory ascites  and    
hyponatremia   is  highly  useful  in  preventing  the  occurrence of  type  2  
hepato renal  syndrome. 
Pentoxyphylline  is  a  non selective  phosphodiesterase   inhibitor   which   
has   been  tried  in  patients   with  alcoholic  hepatitis. In  one  study,  its  use  
was  associated   with  40%  reduction  in   mortality,  thought  to  be   
secondary   due  to  a    65%   reduction  in  the  occurrence  of  hepatorenal  
syndrome.  Patients  in   this  study  were  quite   ill , with  jaundice  and   
Maddrey  discriminant  factor    more  than  or  equal  to   32.   
 
 
 
 
 
 
 
 
 
 
  25   
 
EVALUATION  OF   RENAL  FAILURE  IN  PATIENTS  WITH  
CIRRHOSIS: 
Patients  with  cirrhosis   who   are   at   risk   for   renal  injury  should  
undergo  regular  evaluation    to  detect   renal  dysfunction  at  the  earliest  
because  it  is  an  important   risk  factor   impacting   the  survival   the  of  
these  patients  before  and  after    liver    transplantation    and  there  is  a  
significant  improvement  in  morbidity and   mortality  who  undergo  liver   
transplantation  earlier  based  on  their  MELD   scoring   which  takes  into  
account  their  status  of  renal   reserve. 
Apart  from  conventional   bio  markers  like  blood  urea,  serum  
creatinine,  urinalysis  for  deposits  and  casts  various   other  tests  should  be  
performed  to  find  out  if  it  is  prerenal  failure  or  the  more  severe   
hepatorenal  syndrome  because  prerenal  failure  improves  with  intravascular  
volume  expansion  where as  hepatorenal  syndrome  is  difficult  to  treat. 
The  tests  include 
 1.Serum  creatinine :   
This  is  to  be  measured  everyday  in  patients  with    acute   renal  
dysfunction .  An  increase  in  serum  values  by  0.3  to  0.5  mg/dl   indicates   
severe  reduction  in  glomerular   filtration  rate. 
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2. Serum  electrolytes: 
Serum  sodium  and   Potassium   should  be  measured   frequently   in  
these  patients.  Dilutional  hyponatremia  is common   in  these  patients  and   
the  presence  of   hyperkalemia  necessitates  the  withdrawal  of  potassium  
sparing  diuretics. 
3.Urinalysis: 
24  hour  urine   samples   should  be  examined  in  these patients   for  
urinary  sediment  abnormalities   and  presence  of  significant proteinuria    
favours    the   presence  of  intrinsic  renal   failure  rather  than  functional   
renal  failure. 
4) Ultrasound  Abdomen: 
Urinary    tract   obstruction   should   be   ruled out   which  can  cause    
post  renal  failure.  Presence  of  contracted kidneys   indicates  the  presence  
of  chronic  kidney  disease . Presenc of   normal  kidneys  is  suggestive  of  
functional   renal  failure. 
5) Renal  biopsy: 
 Renal  biopsy  can  be  tried  when  intrinsic  renal failure   is  suspected  
and  the  cause  of  it  could  not  be  identified. It  also  helps  in  making  a   
decision   about  the  need  for  combined liver   and  kidney  transplantation   
such  as  in  patients  with  coexisting renal  dysfunction.  But  renal  biopsy  is  
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contraindicated  if  the  patient has  got  coagulation  abnormalities  or  active  
bleeding. 
 
EVALUATION  OF  LIVER  FUNCTION: 
Apart  from  liver  function tests   and  abdominal  ultrasonogram , a  liver  
biopsy  can  be  performed if  the  cause  of  liver  cirrhosis  could  not  be  
identified  and  there  are no  active  bleeding  or  coagulation  abnormalities. 
 
ASSESSMENT   FOR   BACTERIAL  INFECTION : 
A  high  degree  of  suspicion  is  necessary   to  identify  bacterial  
infection  because   these  patients  may  not  have  an  elevated  leukocyte  
count  due  to   hypersplenism  . Cirrhotics  with  ascites   must  have  a    
diagnostic   paracentesis   for  ascitic  cell  count  and  culture. 
A  chest    x-ray  must  be  taken  to  rule  out  any  respiratory focus  of  
infection. Blood  and  Urine  cultures  must  be  done . 
 
ASSESSMENT  OF  RENAL  FUNCTION: 
To  date  plasma  creatinine  is  the  most commonly    used  method  to  
evaluate   the  status  of  renal  function. But  it  is  highly  inaccurate  and  
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inferior  compared  to  the  measurement  of  glomerular  filtration  rate.  
Glomerular  filtration  rate  is   defined  as  the amount   of  plasma  that  is  
filtered  through  glomeruli   per  unit time.  
Normal  GFR  varies  according  to  age, sex  and  body  size. In  young  
adults  it  is  approximately  120-130 ml/min/m2   and  it declines  with   age. 
The  gold  standard   procedure  for  measurement  of  GFR  is  urinary  
clearance  of  an  ideal  filtration  marker.  An  ideal  filtration  marker  is  one  
that  is  freely  filtered  at  the  glomerulus , present    at  a  stable   plasma  
concentration  and  one  that  is  not  reabsorbed  ,secreted  or  metabolized  by  
the  kidney. 
The  ideal  filtration   marker  is  inulin. However  this   is  rarely  used 
and  alternative  markers  like  iohexol  and  iothalamate  are  more commonly  
used. Apart  from  being  expensive , it  also  poses  high  risk for  patients  and  
difficult  to  perform  in  resource  limited  settings. 
Creatinine  is  generated  from  the  precursor  creatine  in  muscle. It  has 
a  molecular  weight  of  113  k DA  and  is  mainly  eliminated  by  kidneys 
through  glomerular  filtration. There  is  some  amount  of  tubular  secretion. 
The  assays  employed  for  estimation  of  creatinine  varies  in  different 
laboratories  leading  to  significant  variation  in  their  levels. 
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 As  a result  of  variation  in  these  processes  especially    creatinine  
generation,  the  cut   off   for  normal  versus  abnormal  serum creatinine   
concentration  differs    among  groups.  
 Serum  creatinine  is  an  insensitive  marker  as    the  GFR  is usually  
reduced   by   50%  before  serum  creatinine  starts  raising above  the  upper  
reference  range. So  far  creatinine   has  been  considered  the  renal   marker  
of  choice because   it  is  a  naturally  occurring  endogenous  compound  that  
is freely  filtered  at  the  glomerulus  and  has  relatively  minor  absorption and  
secretion  by   the  renal  tubules. Though  serum     creatinine determination  
remains  the  most  commonly  used   renal    marker  for estimation    of  
glomerular   filtration  rate,  it   is  known  to  have  a  number  of  inherent  
difficulties  which  affects  its  clinical   reliability. 
 
 FACTORS  AFFECTING   SERUM  CREATININE  
CONCENTRATION: 
1) Older  age  :  
Serum  creatinine  decreases  due  to  reduced  creatinine  generation  from  age  
related decrease   in  muscle   mass. 
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2)    Sex        :      
Female  gender  have  reduced  serum creatinine   because   of  reduced  
muscle mass. 
 
3) Race:     
Serum  creatinine  increases  due  to  higher  race                    
creatinine  generation  as  a  result of   higher average  muscle  mass  in  
African  Americans compared  to  Caucasians.    
   
4)  Diet:    
Vegetarian  diet  causes  a  decrease  in  creatinine  generation  where  as  
ingestion  of  cooked  meat  causes transient  increase   in  creatinine  
generation, however  this may  by   blunted  by   transient  increase  in  
GFR. 
 
5) Body  habitus: 
   A)    A  muscular  person  has  an  increase  in  serum  creatinine   as  
a  result  of   increased  muscle  mass and   increased  protein  intake. 
   B )   Malnourished  /Amputated  person  has  a  decrease  in  serum  
creatinine  from  reduced muscle  mass  and  decreased  protein  intake. 
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                 C)   An  obese  person  does  not  have  a significant change  in                    
creatinine  values  as  the  excess mass is   fat  which  does  not  contribute  to  
creatinine  generation. 
 GFR   can  be  measured  by  timed  urinary  collection  for  creatinine. 
Creatinine  clearance  is  usually  determined  by  using  venous  blood for   
serum  creatinine  and  a  24  hour  urine  sample. For  a  substance that  is  
cleared  by  urinary  excretion  the  clearance  formula  is   
                                        Cx  =  Ux  X   Vx/Px 
where    Ux  is  the  urinary  concentration  of  x  and  V  is  the  urine  
flow rate.   The  term  Ux  X  Vx  represents  the  urinary   excretion  rate  of  
x.If  substance  x   is  freely  filtered  at  the  glomerulus  ,then  urinary  
excretion represents  the  net  effects  of  glomerular  filtration , tubular  
reabsorption and   secretion. 
Because  the  renal  tubules  secrete  creatinine,  measurements   of  
creatinine clearance  significantly  overestimates  the  GFR .   Accurate  
measurements  of creatinine  clearance  also  requires complete   and  carefully  
timed  urine collections. 
       
           
           
  32   
 
Inadequate  urine  collections   yield   spurious  results.  Repeated   
measurements  of    creatinine  clearance  may  overcome  some  of  the  errors. 
Since    the   conventional  methods   used  for   assessing  renal  function   
are  more  prone  to  errors    newer  biomarkers  have  been  evaluated    as   
markers   of   acute   kidney   injury  .  They  include 
1)  Neutrophil  gelatinase  associated  lipocalin: 
A  25  k Da   protein  belonging  to  lipocalin superfamily , NGAL  is   one  
of  the  earliest   markers  of ischemic  or  nephrotoxic  injury   and  is  
raised  in   the  blood  and urine  of  humans  soon  after  AKI. 
In  a  recent  study  , it  was  shown  to  have a   sensitivity  and  specificity  
of  90%  and  99%  respectively for  identifying  AKI.  
 
2)   Kidney  injury  molecule-1 : 
A  transmembrane  protein, expressed   in    the   renal  proximal  tubular  
cells. After  an  acute insult  like   ischemia   or  injury  due  to  use  of  
nephrotoxic drugs  their  levels  are  markedly  elevated  in  urine. 
          
Urinary  KIM-1   seems  to  be  highly  specific for   ischemic  AKI  .   In  
one  study     it   was   demonstrated  to  be  helpful    in  differentiating   
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ischemic  acute  kidney  injury   from   prerenal  AKI .It  is    also  a  
predictor  of  renal  replacement therapy  and   mortality  in  AKI. 
3) N-acetyl  -beta(D) glucosaminidase: 
A  lysosomal  brush  border  enzyme expressed    predominantly  in  the  
proximal  tubular  cells, N-acetyl-beta (D)    glucosaminidase  is     a  
marker  of  kidney  injury    indicating renal   tubular  damage. 
4) Interleukin-18:  
 A  proinflammatory  cytokine  detected  in  the  urine after  acute   
ischemic  proximal  tubular  damage  , IL-18  displays good  sensitivity  and  
specificity  for   ischemic  AKI    with   increase  in  levels  prior  to  serum    
creatinine  by   two  days. 
5) Cystatin –C: 
 Several  studies  have  been  undertaken  so  far evaluating   the  use  of  
serum  cystatin  c  and  cystatin  based  formulas for  detecting  acute  renal  
dysfunction  in  patients  with  decompensated chronic  liver  disease. 
 It  is  a  cysteine  protease  inhibitor  with  a  molecular weight   of  13  k 
DA    which  is  synthesised  in  all  nucleated cells. Due  to  its  small  size  it   
is  freely  filtered  at  the  glomerulus, and  not  secreted  but  completely   
reabsorbed  by  the  renal  tubules and  undergoes  catabolism   there.  So   the  
serum  levels  of  cystatin C are   dependent  on  glomerular  filtration   as  there  
  34   
 
is  no  significant tubular  secretion  , thus  making  it  a  reliable  marker   of  
estimating glomerular  filtration  rate.  
 The  advantage  of  cystatin  C  lies  in  the  fact  that  it   is  virtually  
unaffected  by  age  ( above  one  year) , muscle  mass, gender  and  race.  
Cystatin  based  formulas  are  relatively  simpler when  compared  to  
creatinine  based  MDRD  formulas. 
Several  cystatin  based  formulas  proposed  for  the  estimation of    
GFR    include     Hoek’ s  formula.  Larsson     and  Grubb formula  has   been  
proven  to  be  equally  reliable  in  estimating  GFR. The  major   advantage  in  
using  cystatin  as  a   biomarker   of  renal  injury  is  that  it  can  detect  even  
small  changes  in GFR  and  there  are   no   GFR  blind  areas  with  cystatin  
C. 
       Thyroid  status  of  the  patient  should  be  determined  before estimating   
cystatin  C  levels  as  it  affects  their  concentration  in plasma .  Treatment  
with  corticosteroids  in  patients  with  decreased renal function   has  been  
shown  to  affect  serum  cystatin  C  levels.  
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DIFFERENTIAL  DIAGNOSIS  OF  ACUTE  RENAL  FAILURE  IN   
LIVER  DISEASE: 
  It  is essential   to  identify  the  nature  of  renal  failure   in  cirrhosis 
because  each  type  has  different  line   of  management.       
Parameters  Prerenal failure  Intrinsic  renal  
failure 
 HRS 
History  Excessive  fluid  
loss 
Prolonged   and  
sustained  volume 
loss 
  Decompensated  
and  advanced  
stage  liver  
failure. 
Clinical  Volume  
contraction 
 Infection, use of  
nephrotoxic agent  
or diuretics 
 Refractory and  
tense  ascites 
Response to  fluid 
challenge 
  Present  Absent  Absent 
Urine  sodium <10  >30 <10 
Urinary/plasma 
creatinine 
 >30:1 <20 :1 >30 :1 
Urinary/ plasma 
osmolarity 
 Urine 
osm>plasma osm 
Urine osm= 
plasma osm 
 Urine osm> 
plasma osm 
Urine  sediments Absent  Granular  cast  
with  cellular  
debris 
  Usually  absent 
Ultrasonogram High  resistive  
index 
High  resistive 
index 
 High  resistive 
index 
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History  of   volume  loss  followed  by  onset  of  renal  failure  which   
gets corrected   with  volume  replacement  favours  pre renal   azotemia  where  
as it  is  not  corrected  it  if   it  has  progressed   to  acute  tubular  necrosis. 
Hepatorenal   syndrome  may  or  may  not   have  precipitating  factors 
and usually   responds  to  volume  expansion  with  intravenous  albumin. In    
urinanalysis   presence  of  hyaline  casts  is  normal  and  can occur   in  pre 
renal  azotemia  or  hepatorenal  syndrome  where  as  the presence  of   renal  
tubular  epithelial  cells    favours  the  diagnosis  of acute   tubular  necrosis.  
Urine  sodium,  fractional  excretion  of  sodium, urine  plasma  osmolality  
ratio,  urine  and  plasma  creatinine  ratio  are  not  as  useful  as  examination  
for  urinary  sediments  in  differentiating  the  three   most  important  causes  
of  renal  failure  in  patients with  chronic  liver  disease. 
The  use  of  Duplex   Doppler  Ultrasonogram for   the   assessment  of  
intra  renal  hemodynamics  , and  renal  arterial resistive  index  has   been  
shown  to  have  a  significant    correlation  to  plasma  renin  activity  and  can  
be  tried  in  patients  with compensated     cirrhosis   and  ascites.(44). 
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MANAGEMENT  OF  RENAL  FAILURE  IN  CHRONIC  LIVER 
DISEASE: 
General  measures: 
Cirrhotic   patients  with  acute  onset  renal  dysfunction   should    be    
treated   aggressively  as  early  interventions can   significantly  lower  the   
mortality.  Precipitating  factors  like sepsis  and  blood  loss  from  variceal  
bleeding  due  to  portal  hypertension should  be  identified  and  taken  care  of  
at  the  earliest.  Third generation  cephalosporins  are  the   preferred  drugs  for  
the  treatment  of  sepsis  in  patients  with  cirrhosis    with   ascites. 
Patients  with  type  1   hepatorenal  syndrome  are  more  prone  for  
developing   adrenal  insufficiency  and   treatment  with  corticosteroids have  
been  shown  to  be  marginally  beneficial  in  these  patients. 
           Administration   of  excessive  fluids  should  be  discouraged as  there  is  
increased  risk  of  dilutional  hyponatremia  and  fluid accumulation  can  lead  
to  massive  ascites  and  respiratory   distress  in these  patients. 
After  the  onset  of  renal  failure,   the  use  of  potassium sparing  
diuretics   should  be  discouraged    as  there  is  a possibility of  developing  
hyperkalemia   which  can   lead  to  cardiac  conduction abnormalities  and  
sudden   cardiac  arrest.  Loop  diuretics  may  not  be effective  in  this  
situation. 
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Patients  with  intractable  and  refractory  ascites  should be   treated  
with  repeated  abdominal  paracentesis   along   with  adequate intravascular  
volume  replacement  like  intravenous  albumin  at  a  dose of  eight  grams  per  
liter   of  fluid  removed. 
Diuretics  should  be  discontinued  if  the  renal  dysfunction  is  due  to  
overuse  of  these  drugs  and  isotonic  saline  can  be  given  if there  is  
hyponatremia   along  with   volume  contraction  in  the  absence  of  
extravascular  fluid  accumulation. 
The  treatment  of  hepatorenal  syndrome  is  improving  the  effective  
arterial volume  through  volume  expanders  , reducing  the  extent  of  
splanchnic vasodilation  through  vasoconstrictors  and  elimination  of  portal  
hypertension   through  transjugular  intrahepatic  portosystemic  shunt and  
elimination  of  toxins   produced  by  sepsis  which  causes  circulatory 
dysfunction. 
Hemodialysis  and    CVVH    have    been    tried    as  a  treatment  
option for  patients  with  hepatorenal  syndrome  who  are   candidates  for   
liver  transplantation   as  a  bridge  therapy.  But  there  has  been  no  studies 
which  has  validated  their  advantage  over  pharmacological   therapy  like  
vasoconstrictor  administration. 
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Also  the  procedure  is  can  be  complicated  by  severe  bleeding 
episodes  which  can  lead  to  hypotension  and   infection. So it  is  better  to  
reserve  this  treatment  to  those  who  have  no  satisfactory  response   to   
vasoconstrictor  therapy  and  also  in  those  who  develop  severe  life  
threatening  hyperkalemia  and  refractory  fluid  accumulation   which    results  
in  respiratory   distress. 
 
PROGNOSIS  OF  RENAL  FAILURE   IN  CHRONIC  LIVER  
DISEASE: 
Renal  failure  in  a   patient   with  liver  disease  has  got a  dismal  
prognosis.  It   depends  on  the  type  of  renal  failure. Pre renal  azotemia  has  
got  a  better  prognosis  where  as  those  with hepatorenal  syndrome  have  got  
the  worst  prognosis.  Without  liver transplantation  the  mortality  rate  is  
50%  at  one  month  and  80% at  six  months. 
The  use  of  vasoconstrictor  therapy  does  not  improve the   mortality  
rate  in  these  patients  with  hepatorenal  syndrome  but if  they  respond  to  
vasoconstrictor  therapy  they  have  a  significant level  of  better  prognosis  
than  those  non  responders(43)  . 
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PREVENTION  OF  RENAL  FAILURE  IN  CIRRHOSIS: 
The  patients  with  cirrhosis  at  risk  of  developing bacterial    infections  
include   
1)  Child  pugh  score  >10 
2) Ascitic   fluid  protein  content < 1.5 grams/dl 
3) Plasma  sodium  level  < 130  mmol/L 
4) Serum  bilirubin  > 3 mg/dl . 
In   these  patients   prophylaxis  with  oral  norfloxacin  400  mg/day has   
been  shown  to  reduce  the  incidence  of  spontaneous  bacterial peritonitis .  
The  proposed  mechanism  for  this  is  the  inhibition  of  translocation  of  
microbial  organisms  from  the  gut  to  the  peritoneum. 
Also   albumin  given  on  the  day  of   admission  and  on  day  three 
intravenously  has   been  shown   to  reduce  the  incidence  of  spontaneous 
bacterial  peritonitis  and  hepatorenal  syndrome. 
Avoiding  diuretic  abuse  and   judicious  use  of   aminoglycosides  will  
go a     long   way   in  preventing  the  development   of   iatrogenic   renal  
failure. 
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RENAL  FAILURE  AND  LIVER  TRANSPLANTATION: 
Patients  at  risk  of  renal  failure  are  suitable  candidates  for liver  
transplantation .  Pre   treatment   with  vasopressors  and  albumin  has  been  
shown  to  improve  the  outcome    after  transplantation. 
Studies  have  shown  that  in  cirrhotics  who   have  refractory  ascites 
but  not   yet  developed  hepatorenal  syndrome, liver  transplantation has  been  
shown  to  have  a  dramatic  improvement   in  renal  function and  this  shows  
that  liver  transplantation  should  be  done  as  early  as possible  in  cirrhotics  
who  are  suitable  candidates  for  liver  transplantation. 
 
COMBINED  LIVER   KIDNEY  TRANSPLANTATION: 
     The  exact  factors   determining  the  need  for   combined liver  and   
kidney  transplantation  have  not  been  identified  as  yet. Presence  of  
hepatorenal  syndrome  alone  does  not  necessarily  need combined   liver  
transplantation  because  only  liver  transplantation has  been   shown  to  
reverse  the  renal  dysfunction  in  these  patients. But   the  duration  for  which   
the  patient  has  undergone renal  replacement   therapy  before  undergoing  
liver  transplantation  is a  relatively  reliable  indicator   for  determining  the  
presence  of  irreversible renal  failure   which  necessitates  combined  liver  
kidney  transplantation. 
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Studies  have  shown   that  patients  who  have   undergone  renal  
replacement for  atleast   three  months   before  undergoing  transplantation  
have  an  improved  survival   with  combined  liver  kidney  transplantation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  43   
 
MATERIALS  AND  METHODS 
 
INCLUSION CRITERIA:  
After they gave informed consent, 50 patients   undergoing   treatment  
for  chronic liver  disease    as  in- patients   in  the  Department   of  General 
Medicine, Tirunelveli  Government  Medical  College,Tirunelveli   participated  
in the  study. 
The  criteria  for   chronic   liver   disease   is   defined   by 
1. Compatible  clinical  profile  (History, Ascites  with  or  without  
jaundice) 
2. Ultrasound    evidence ( reduced  liver  span/altered echo texture  of   
liver)    
3. Biochemical    profile (abnormal   liver   function   tests  or reversal  of   
albumin- globulin ratio ) 
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EXCLUSION CRITERIA: 
• Age  > 60  years 
• Known  primary  renal  disease 
• Refractory  ascites 
• Severe  encephalopathy 
• History  of  recent  gastrointestinal  bleed 
• Thyroid  dysfunction 
• Diabetes  mellitus 
•  Hypertension 
•  Patients  receiving   corticosteroid  
therapy,   Angiotensin  converting  enzyme    
     inhibitors.  
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METHODOLOGY 
This   analytical  study  was  conducted  in  50  eligible  patients  admitted  
for  chronic  liver  disease  with  apparently  normal  renal  function  in  the  
medical  wards  in  our  hospital  from   August   2011  to  August   2012. 
All  patients  underwent  a  thorough  clinical  examination, including   
medical  history.   
Urinalysis  including   24  hours  urine   volume   and  urine   creatinine  
were  done  after  stopping  diuretics  for  three   days  and  biochemical  profile  
including  liver  function   tests,  viral  markers  for  hepatitis B,  renal  function   
tests  were   done   and   results  were   noted . 
After  assessing  thyroid  status  of  the  patient  ,serum   cystatin   was  
estimated  with    the   same   sample   used    for   evaluation   of    plasma  
creatinine.    Data  about  demographic   variables, clinical    features  were 
collected  using  a  proforma. 
Ultrasound   Abdomen  was   done   in  all  the  patients   to  assess  liver   
size  and  echotexture ,  presence  of  splenomegaly, portal   vein  dilatation,  
presence  of  collaterals  around  spleen,  presence  of  ascites  and  structural 
renal abnormalities. 
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Estimated   Creatinine   clearance   was  calculated  using  Cockcroft- Gault  
formula(CGF) 
           (140-Age) x Body weight in kilogram   
             Serum   Creatinine  x  72. 
If  the  patient  is  female  the  above  value  has  to  be  multiplied   by  0.85. 
 
Measured  creatinine  clearance  was calculated  by the  formula   
 (Urine creatinine x 24 hours urine volume) 
 serum creatinine. 
This value was divided by 1440 to get the GFR in ml/min 
 
Estimated  creatinine  clearance  using  serum  Cystatin  was  calculated  
using  Hoek’ s formula   , GFR = -4.32 + ( 80.35 X  1/Cys C).   Comparison of 
GFR  obtained     by  the  above  methods  was  done . 
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STATISTICAL   ANALYSIS 
The   continuous  variables  of    two    groups  of   study  subjects were 
compared  between  attributes  by  student  independent  ‘t’ test. More  than  two  
groups  of  variables  were  compared  between  the  categories  by   ANOVA 
(Analysis  of  variances)  and  the  significance between  the  two  groups  were  
tested  by  post  coc  test  of  Bonferrani. The  category  variables  were  
compared  by  Chi square  test. The  above statistical   procedures  were  
performed  by  the  statistical  package IBM  SPSS 20. The  ‘p’  value  less  than  
0.05 (p<0.05)   was  considered as   significant. 
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OBSERVATIONS  AND  ANALYSIS 
50   patients  with  chronic  liver  disease  who  fulfilled  the  inclusion  
criteria  participated   in  the  study. 
The   observations  made  are  as  follows: 
AGE:  
Among  the   study   group   the   minimum  age  was   24  years   and   
maximum  age  was    58  years. 
 The mean  age was  43.5   years. 
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Table1: 
AGE GROUP 
(YEARS) 
NUMBER OF 
PATIENTS 
PERCENTAGE 
20-29 03 06% 
30-39 11 22% 
40-49 23 46% 
50-59 13 26% 
TOTAL 50 100% 
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SEX DISTRIBUTION:    
Of  the  50 patients  40  were  male  and  10  were female. 
Table2: 
Age group 
(Years) 
Male 
(number) 
Percentage 
(%) 
Female 
(number) 
Percentage 
(%) 
20  to 29 01 2.5 02 20 
30 to 39 08 20 03 30 
40 to 49 22 55 01 10 
50 to 59 09 22.5 04 40 
TOTAL 40 100 10 100 
 
Chart2:
 
Sex distribution
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CLINICAL  CHARACTERISTICS OF STUDY PARTICIPANTS:  
Study  subjects    according  to  their   bio- chemical  parameters  are as 
follows: 
Table4: 
Variable 
Serum 
Bilirubin 
(mg/dl) 
Serum 
Albumin 
(gm/dl) 
PT 
(Sec) 
 
blood 
urea(m
g/dl) 
 
Serum 
Creatinine 
(mg/dl) 
Serum. 
Cystatin 
(mg/L) 
Urine 
value 
Urine 
Creatinin
e  
Mean 5.0 3.2 14.9 28.0 0.93 1.4 1446.8 59.1 
SD 5.7 0.6 3.0 9.3 0.19 0.5 424.7 13.2 
Min 1.0 1.8 12.0 15.0 0.6 0.73 400.0 43.0 
Max 25.5 4.6 27.7 54.0 1.4 3.10 2300.0 102.0 
 
The  mean  serum  bilirubin   was  5  mg/dl , serum  albumin  was 3.2  
mg/dl, mean   prothrombin  time  was  14.9  seconds, serum  creatinine  was  
0.93  mg/dl,  mean  serum  cystatin  value  was  1.4  mg/L 
The   blood  urea  levels   were  within  normal  limits  and  did  not  rise  
markedly  even  in  patients with diminished  GFR  indicating  that  it  is  an  
unreliable  marker  for  assessing  renal  function  . 
  The  mean  blood  urea  level  was  28 mg/dl. 
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COMPARISON OF BIOCHEMICAL CHARACTERISTICS  BETWEEN  
CASES WITH   KNOWN  CAUSES  AND  IDIOPATHIC: 
The bio- chemical parameters  were  compared   in cases with  known  
cause  for  chronic  liver   disease  and  those  with  idiopathic  cirrhosis.   
Table5: 
variables 
Causes Differ
ence 
b/w 
means 
‘t’ df 
Signifi
cance. 
Present n=35 Absent n=15 
Mean SD Mean SD 
Sr.bilirubin 6.0 6.4 2.1 1.1 3.9 2.241 48 P<0.05 
Sr.  albumin 3.2 0.6 3.1 0.5 0.1 0.429 48 P>0.05 
PT (Sec) 15.1 3.3 14.4 2.1 0.7 0.822 48 P>0.05 
Blood urea 27.6 9.3 29.1 9.4 1.5 0.516 48 P>0.05 
Sr. Creatinine 0.9 0.2 1.0 0.2 0.1 2.524 48 P<0.05 
Sr. Cystatin 1.36 0.57 1.44 0.35 0.08 0.444 48 P>0.05 
Urine volume of 
24 hours 
1458.9 448.5 1415.6 370.1 43.5 0.320 48 P>0.05 
24hr. 
U.Creatinine   
59.7 15.0 59.6 7.3 2.1 0.516 48 P>0.05 
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It   was  found  that  there was no significant difference in   serum 
albumin,  PT (Sec),  blood  urea, serum cystatin, urine  volume of 24 hours and 
urine creatinine of 24 hours (P>0.05). The serum bilirubin of subjects with 
known causes was  6.0±6.4   and subjects with idiopathic causes   was 2.1±1.1 
and the  difference was statistically significant (P<0.05). Similarly the  serum  
creatinine  of  subjects  with known causes was  0.9±0.2  and  subjects  with   
idiopathic causes was  1.0±0.2  and  the  difference  was  statistically  
significant (P<0.05). 
 
GRADING   OF   SEVERITY  BY  CHILD –PUGH SCORE: 
Patients  with  score  5 to 6  fall under  Grade  A.  Grade B  includes  
scores  from 7 to 9.  Scores   above  9  is  Grade  C. Of  the  50 patients, sixteen 
patients   belonged   to Grade A, 21 came  under  Grade B  and  13  were in   
Grade C. 
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Of  the  16  subjects in  Child  Pugh  A  group  10    ( 62.5%)  had  a 
serum  creatinine   value  of  less  than  one  mg/dl  and  none  of  them  had  
creatinine levels  above 1.2  mg/dl. 
Of  the  21  subjects  in   Child  Pugh  B , 20  had  their  serum  creatinine  
levels within   normal  limits  where  as  only  one  patient  (4.76%)  had  serum 
creatinine  above  1.2  mg/dl. 
Of  the  13  subjects  with  Child   Pugh  score  C, six (46.13%)  of  them  
had  their  creatinine   levels   less  than  one   and  only  one  patient (7.69%)  
had his  values  more  than  1.2  mg/dl. 
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Pugh    C  had  cystatin  levels  less  than  one.   Eight  (61.53%)  out  of   
thirteen  patients  had  serum  cystatin  levels  more   than  1.5  in  Child  Pugh 
C . This  shows  that   serum  cystatin  levels  increase  as  the  degree  of  liver  
dysfunction  increases. 
The   mean  cystatin  level  in  Child Pugh  A  was  1.05  where as  it was  
1.47 in Child  Pugh  B and  1.66  in  Child Pugh C. 
 
SERUM  CREATININE  AND   GFR  : 
Study   subjects  were  classified  into  three  groups  based  on  their  
GFR calculated  based  on  cystatin   C . Group  I   had  a  GFR  < 50 ml/min. 
Group  II  had   GFR  between   50-90 ml/min   where  as  Group  III  had  GFR  
above  90 ml/min.                     
Table  no  10: 
 S.Cr<1 mg/dl S.Cr 1 to 1.2 
mg/dl 
S.Cr  >1.2 mg/dl 
Group I 05 14 01 
Group II 18 05 01 
Group III 05 01 00 
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Table no 12: 
Child  pugh  
score 
GFR <50 ml/min 50-90 ml/min >90  ml/min 
A 01 10 05 
B 06 13 02 
C 06 07 00 
 
Only  one patient (6.25%)  in  Child  Pugh  A had  GFR  <50 ml/minute 
where as six  patients    (46 %)  in  Child  Pugh  C  had   GFR  <50 ml/minute  
when  creatinine  clearance  is  measured. 
 
COMPARISON  OF  GFR  BY VARIOUS  METHODS:  
The  patients  were  grouped  under   three  Categories.  Group 1 included   
patients  with  GFR  <50 ml/min  according  to  Hoek’s  formula. Group 2  
included  those   with  GFR between 50 to 90 ml/min. Group 3  included  those 
with   GFR  above 90 ml/min. 
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On  comparing  GFR  values  obtained  by  the  three  methods, only  
seven(14%)   out   of  fifty  patients  had  GFR  50 ml/min  by CGF, whereas   
20(40%)  was  found  to  have  GFR  <50 ml/min  when  cystatin  based  
formula  is  used.  13 (26%)  subjects  fell under group I   when  creatinine   
clearance   was  measured.. 
This  shows  that  cystatin  C  based  equations  have  better  sensitivity   
in identifying  small  decline  in  glomerular  filtration  rate  when  compared to  
other  methods.       
Table  no 14: 
Methods Mean SD 
ANOVA 
‘F’ 
Sig. 
Significantly 
differed Measures 
CGF 76.3 20.7 
7.060 P<0.001 
CGF& Hoek 
Hoak 54.4 21.1 CGF& Mea GFR 
Measured 
GFR 
65.3 22.9 
Hoek  and measured 
GFR 
 
The above table compares the CGF, Hoek and  measured  GFR. The 
mean of CGF was   76 ±   20.7, which significantly  differed  with other 
methods namely Hoek (54 ±   21.1 )   and   measured GFR (65.3 ±  22.9) . P  
value was found to be < 0.001  which is   significant. 
 
 
statisti
RENA
their  
betwee
under 
disease
 
 
1
1
1
1
1
2
N
U
M
BE
R 
O
F 
PA
TI
EN
TS
The  diffe
cally    sig
L FUNC
The   stud
GFR. Gr
n  50 to 
 Group   
  due  to  
0
2
4
6
8
0
2
4
6
8
0
Alcoh
rence  be
nificant  
TION AN
y  subjec
oup 1 wi
90  ml/mi
3.The  GF
various  e
ol Hb
ETIO
RENAL 
tween  H
 (p  <0.05
D ETIO
ts  were  
th GFR  
n  and  th
R  was 
tiologies.
sAg W
LOGY OF CH
FUNCTI
68
oek  proc
) 
LOGY:
grouped 
less than 
ose  with
 compare
 
ilson s A
RONIC LIVER
ON AN
 
edure  an
into  three
50 ml/m
  GFR  m
d   in  sub
utoimmune
 DISEASE
D ETIOL
d   measu
 categorie
in, Group
ore than 
jects wit
Idiopathic
OGY
red    GF
s  accord
 2  with
 90 ml/m
h  chronic
Group
Group
Group
R was  
ing  to  
  GFR  
in  fall  
  liver  
 
 1
 2
 3
  69   
 
Out   of  26  alcoholics, eighteen  subjects (69.23% ) had GFR  less than 
50 ml/min , and  the  eight (34. 78)   had  GFR in the  range  between 50-90 
ml/min and   none  of  them  had   GFR   above   90 ml/min. 
Of  the six patients who are HbsAg   positive only two (33.33%)  had  
GFR  less than 50   ml/min ,where as four  patients (66.66%)  had GFR above 
50 ml/min. 
Chronic   liver  disease  associated  with  Wilson’s disease  had   GFR  
above 50 ml/min. 
  
SERUM  ALBUMIN  AND  RENAL  FUNCTION: 
Our  study  group  was  divided  into  three  categories  based  on  their   
GFR   and    serum   albumin   level  distribution  in  all  the  three  groups  were  
noted. 
Table no 15: 
S.Albumin(mg/dl) Group 
1(GFR<50ml/min)
Group 2 
(GFR50-90 
ml/min) 
Group 3(>90 
ml/min) 
<3.0 05  05 00 
3.0-3.5 14 16 02 
>3.5 01 01 06 
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DISCUSSION 
We  analyzed  the  extent  of  renal  dysfunction  in  50  patients  with  
chronic liver  disease. Till  now  creatinine  based    equations   for  estimating 
glomerular  filtration  rate  are   the  most  commonly  used   methods.These  
have  the   advantage  of  being  free  of  urine   collection  errors. 
In  our  study, even  in  patients  with  glomerular  filtration  rate  less  
than  50ml/min   serum  creatinine   levels  were  found to  be  normal  and   
failed  to  raise  above  the  upper   reference  limits. 
The   study  by    McAulay et al (44)  also  reported  similar  findings  that  
serum  creatinine  is   a  poor  indicator  of    renal   function   in  chronic  liver  
disease  and  was  found  to  be  within  normal   limits, even  when  GFR  has  
reduced  significantly. 
The  study  by  Caregaro et al(45)  showed  that  serum  creatinine  had  
only  18.5%  sensitivity   in  detecting   reduced  renal  reserve   in patients  with  
cirrhosis  at  risk  of  renal  dysfunction. 
Papadakis  and  Arieff(46)   had  also  reported  similar   observations   that 
use of  serum   creatinine  solely  as  a  marker  of  renal  dysfunction  is  highly  
erroneous  and  leads to   a  spuriously   good  renal  reserve  in  these  patients. 
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This  may  be  due  to  the  fact  that  the  steady  state  concentration  of  
creatinine  is  low  in  cirrhotics. The  various  factors  contributing  to  reduced  
serum  creatinine  levels   include  malnutrition   and  reduced   muscle  mass  in  
these  patients.    Also  the  hepatic  synthesis  of   creatine  which   is  the  
precursor  of  creatinine  is  reduced     by   40  to  50 %  in  these  patients.  
Renal  tubular  secretion  of  creatinine   also  increases  in  these    patients , 
which  further  decreases  serum  creatinine  levels. 
Our   study   also  showed  that    creatinine  clearance  by  Cockcroft –
Gault   formula  overestimates   GFR   in  chronic  liver  disease  patients.  This   
is  in  agreement  with   the     study   done  by   Skluzacek  et al   comparing   
Cockcroft Gault   and   MDRD   based    formulas   with   iodine  125-
iothalamate  clearance  which   has  also  shown  that   both  CGF  and                    
MDRD  are  inaccurate  and   overestimate   GFR.  
The  study  by  McAulay et al  reported  similar  observations  and  also 
showed that  among    the  creatinine   based  equations  MDRD  formula    is  a  
better   method  for  estimating   GFR. This  takes  into  account   the  patient’ s 
age, sex, race, serum  creatinine , serum    albumin  and  blood  urea  nitrogen  
levels. 
This   may  be  due  to  the  fact  that  body weight  is  a numerator  and  
serum  creatinine  is  a  denominator  in  Cockcroft Gault  formula  . Increased  
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body  weight  due  to  ascites  and  edema   with   reduced  serum  creatinine   
contributes  to  the  falsely  elevated  GFR  by this   method.  
In  our   study    serum  cystatin  C  was  found  to  raise   as  the   renal  
function    deteriorates   indicating    that  it   could  be   a  reliable  marker  for  
renal  dysfunction  in    decompensated    chronic  liver  disease  patients.  40%   
of  the  patients  in  our  study   had    GFR < 50 ml/min  when   cystatin  based       
formulas  were  used   compared  to   14%  when    creatinine  based                     
Cockcroft  Gault   formula  was  used. 
Our  study  is  in  accordance  with   that   of  the  study   by  Poge(47)  et 
al which  was  done   to  evaluate  the  diagnostic   accuracy  of   cystatin   based  
formulas  namely  Hoek  and   Larsson  equations   and   it  showed   that  there  
was  a  significant  improvement  in    estimation   of  GFR  with  lower  bias  
and   higher  precision  than   creatinine   based    formulas  but   none  were  as  
accurate  as  inulin  clearance. 
The   study    undertaken   by  Herget- Rosenthal (48)  to  identify  the   
better  method  in   detecting    the  occurrence   of  renal  dysfunction   between  
serum  cystatin  C  and  serum   creatinine  and   , serum  cystatin  C  detected   
ARF    earlier  than  serum  creatinine  by   1.5 +   6  days (Risk  criteria) and 
1.2  + 0.9  days  by  injury  criteria. 
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Our   study  is  in agreement   with  the  Rocco Orlando  et al (49).  Their  
study  showed  that    serum  cystatin C  had a  good  diagnostic  sensitivity  
(88% ) when  compared   to  serum  creatinine  (23% )  to  detect  renal   
dysfunction.   in   cirrhotic   patients. 
Newman   et al (50)  reported  similar  results  that  not  only   serum  
cystatin   C  is a  better   marker   than   serum   creatinine   and   that  it    is  
more  sensitive  to  detect  smaller    changes   in  GFR. In  our   study  too  
serum  cystatin  proved   to  be  better  than  other   methods. 
In   a   meta  analyses  by  Vikas  Dharnika et al(51),  Cystatin C  has  got  
a greater  correlation   coefficient  than   creatinine   and  the   correlation  of  
GFR  with  the   reciprocal  of    Cystatin   C  increases   as  the  renal  function   
deteriorates.  
In  our   study  measured   creatinine  clearance  by  timed  urine  
collections   was  better  than   serum  creatinine   and  estimated   GFR  by  
Cockcroft- Gault  method  but   less   accurate   than  cystatin    based   
formulas. 
The  study  by  Proulx  et al (52)  showed   that  though    Inulin    clearance  
is   the   most    accurate   method   for  estimating   renal  function  ,  it  is  
practically  impossible  in   resource  limited   settings   and   though   calculated    
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GFR   by  timed  urine   collection   methods  overestimates  true   GFR  it is  
preferable  to  that  of  Cockcroft   Gault  formula. 
The  overestimation  of  true  GFR   may   be  due  to  the  fact  that  there   
is  increased    tubular    secretion    in  the   setting  of   lower  glomerular  
filtration   leading   to  falsely   high  values  of   glomerular  filtration   rate. 
The  study  by   Papadakis  .and   Arrief   and    another   study  by  
Caregaro  et  al  have  supported   this   observation   by  concluding  that   
calculated  creatinine   clearance  may   be  an aid  to  true   GFR   in  the   
absence  of   Inulin   clearance.In    our   study    there  was   no  statistically  
significant  correlation  between  the  levels  of  serum  albumin  and  renal  
function.  
This  is  in  agreement  with   a study   by  Hampel  et  al(53)  which  also  
had  reported  that    serum  albumin   levels  did  not  correlate  with  degree  of  
renal  dysfunction and   it  was  not  considered  to  be  a  significant   risk  
factor  for  the  development  of  renal  dysfunction. 
Our  study  has  also  shown  that   patients  with  alcoholic  cirrhosis  had  
adverse  renal  function  compared    to  those  with  Hb sAg  positivity.  69.23%  
of  alcoholics  had  GFR   below  50  ml/min  where  as  only  33.33%  of  
HbsAg  positive  individuals  had  GFR   <50  ml/min. 
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In  our  study  blood  urea  levels  were  found  to  be  normal  even  when  
GFR  was  grossly  reduced  . This  may  be  due  to  their  reduced  synthesis  in   
patients   with  decreased  hepatic  function. Also  they  may  falsely  increase    
when   there  is  gastrointestinal  blood  loss. Hence  they  are  unreliable  for   
assessing  renal   function  in  cirrhotics. 
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CONCLUSION 
1)  In  patients  with  chronic  liver  disease  ,plasma  creatinine  alone  is  
a  poor  marker  for  detecting  renal  dysfunction. 
 
2) Creatinine  based  Cockcroft- Gault  formula  grossly  overestimates  
renal  function. 
 
3) Serum  Cystatin C  and  cystatin  C  based  formulas  for  estimating  
GFR    is  a  better  marker  of  renal  dysfunction  compared  to  serum  
creatinine  and  hence  should  be used  for  assessing  renal  function  
for   making   necessary  dose  adjustments  in  these  patients. 
 
4) Measured  creatinine  clearance  though  not  accurate  as  cystatin C   
based  formulas   is  better  than   Cockcroft  Gault  method.  
 
5) Alcoholics  develop  severe  renal  dysfunction  compared  to  patients   
with  cirrhosis  due  to  other  causes. 
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PROFORMA 
 
NAME: 
AGE: 
SEX: 
BODY WEIGHT (KG): 
CAUSES  OF  CIRRHOSIS : 
ALCOHOL HEPATITIS 
-B 
HEPATITIS 
-C 
WILSON’ S AUTOIMMUNE 
 
PRESENTING  COMPLAINTS: 
DURATION: 
HISTORY:  
1)FEVER 
2)DIARRHOEA 
3)VOMITING 
4) ABDOMINAL  PAIN 
5) RAPID  PROGRESSION  OF  ASCITES 
6)  GASTROINTESTINAL  BLEED-  
    MELENA/HEMATEMESIS 
               
   
 
7) GUM  BLEED 
8)DRUG HISTORY - 
DIURETICS/ANTIBIOTICS/RADIOCONTRAST AGENTS 
 CLINICAL EXAMINATION: 
1) GENERAL  CONDITION 
2) PALLOR 
3) JAUNDICE 
4) SIGNS OF  LIVER CELL FAILURE 
5)  BLEEDING TENDENCIES 
6)  ABDOMINAL  DISTENSION 
7) UGI  BLEED 
8) PEDAL  EDEMA 
9) OLIGURIA 
10)VITALS- PULSE/BP/RESPIRATORY  RATE/TEMPERATURE 
11) ASCITES 
12)  LIVER  SIZE 
 13) SPLENOMEGALY 
14)  SENSORIUM                   
              
 
   
 
LAB INVESTIGATIONS: 
THYROID PROFILE LIVER   FUNCTION  TESTS: 
SERUM  BILIRUBIN: 
TOTAL PROTEIN: 
SERUM ALBUMIN: 
SERUM GLOBULIN: 
ASPARTATE  AMINOTRANSFERASE(AST): 
ALANINE  AMINOTRANSFERASE (ALT): 
AST/ALT  RATIO: 
PROTHROMBIN  TIME: 
BLOOD  UREA: 
SERUM  CREATININE: 
SERUM  ELECTROLYTES: 
 
 
 
 
   
 
URINE  ANALYSIS: 
URINE-  ALBUMIN 
                  DEPOSITS 
   24  HOUR  URINE  VOLUME: 
  24  HOUR  URINE  CREATININE: 
SERUM  CYSTATIN C: 
HBsAG-  POSITIVE/NEGATIVE 
ANTI  HCV  ANTIBODY 
ULTRASOUND  ABDOMEN: 
LIVER:  SIZE IN  CENTIMETER/ECHO TEXTURE 
ASCITES- NIL/MODERATE/MASSIVE 
SPLEEN-SIZE/COLLATERALS 
PORTAL  VEIN  DIAMETER 
KIDNEYS-SIZE/ECHO TEXTURE/CORTICO  MEDULLARY 
DIFFERENTIATION. 
 
 
   
 
MASTER CHART 
s.no  name  age se
x 
b.wt(kg
) 
Cause  s.br  S.al
b         
Asc  PT(Sec
) 
H.en
c 
Childpugh  Bl ur  S.C
r        
Egfr(CGF
) 
s.cys(mg/
L  
Egfr(Hoek
)  
24 hr U  24  . 
Vol            cr 
mea 
GFR 
1  Isakki  36  m  54  Alc  4.2  2.9  e.con 13  min  10       ( C )  20  0.8  97.5  0.995  76.43  190
0 
54  89.06 
2  Thangam  27  f  48  Idio        2.8  4.2  none  13    nil    6       (A )  28  0.8  80.04  0.9  84.92  210
0 
49.5  90.23 
3  Mari                36  f  50  Auto  10.
2 
3.7  e.con 16   min   9        (B)  36  0.9  68.2  1.33  57.45  110
0 
79.1  67.62 
4  Jameela  26  f  42  Wil  3.8  3.4  e.con 23    min   12      (C)  48  1.1  51.39  1.5  51.11  990  83.6  52.29 
5  Baskaran  45  m  78  Alc  10.
6 
3.1  e.con 13  nil   9        (B)  34  1.1  93.56  1.4  53.07  159
0 
97.6  97.6 
6  Fathima  38  f  50  HbsA
g 
3  4  none  12   nil    6       (A )  28  0.6  100.34  0.73  105.74  230
0 
65  103.8 
7  Irulandi  50  m  67  Idio  1.7  3.2  none  13  nil    6       (A )  22  0.8  93  1  76.03  200
0 
55  84.88 
8  Sankaran  40  m  64  Idio  1.2  3.5  none  14  nil  6        (A )  28  0.8  111.11  0.82  93.66  110
0 
102  97.3 
9  Murugan  40  m  54  Alc  3.1  2.6  p.co
n 
14  nil  11     (C  )  33  0.8  93.75  1.15  65.54  190
0 
54  89 
10  Ganesan  57  m  68  Alc  6.7  3.2  p.co
n 
15  nil  10      (C )  33  0.8  97.98  1.51  48.89  190
0 
50  82.47 
11  Palraj  47  m  75  Alc  4.3  2.4  p.co
n 
15  nil  11     (C )  50  1.4  67.4  1.43  51.86  180
0 
72  65 
12  Kandan  48  m  53  Alc  1.2  3.2  none  12  nil    6      (A)  28  1  67.72  1.54  47.85  150
0 
53.9
9 
55.99 
13  Selvam  40  m  49  Alc  1.5  3.4  none  14  nil   6       (A )  18  0.8  85.06  0.9  84.9  150
0 
46  59.9 
14  Kesavan  45  m  47  Idio  1.4  3.2  none  14  nil    6       (A )  26  1.2  51.67  1.23  60.97  140
0 
66  53.5 
15  Elango  50  m  60  Alc  3.2  3.4  p.co
n 
16  min  11      (C )  26  0.9  83.33  1.5  49.29  140
0 
46.2
5 
49.96 
16  Kalaiselvi  38  m  45  HbsA
g 
2.6  3.4  none  15  nil  7        (B )      28  0.8  67.73  1.44  51.47  130
0 
44  49.65 
   
 
17  Sumathy  55  m  50  Idio  1.2  3.2  e.con 12  nil  7        (B )  22  1.2  41.81  1.62  45.27  100
0 
55  31.83 
18  Sivagami  50  m  54  Idio  2.3  3.2  e.con 12  nil  8        (B )  22  1  59.01  1.64  44.67  150
0 
53.7
5 
55.99 
19  Palani  35  m  45  Idio  1.5  3.7  e.con 13  Nil  5       (A  )  18  1  65.6  1.4  53.07  125
0 
64.5  55.99 
20  Tamilan  51  m  53  Alc  16.
4 
3.4  e.con 15  min  8        (B  )  43  1.4  46.79  2.6  26.58  850  43  18.13 
21  John  38  m  48  Alc  1.2  3.3  e.con 15  nil  6       (A )  20  1  68  1.13  66.78  125
0 
64.5  55.9 
22  Anbu            30  m  40  Alc  1.4  3.3  none  14  nil   6      (A )  22  1  61.11  1.8  40.31  125
0 
48  41.67 
23  Murugan  42  m  46  Idio  1.7  3  e.con 13  nil     6      (A )  18  0.7  87.61  0.8  96.08  111
9 
61.2
5 
68 
24  Baalan  48  m  53  Alc  1.2  3.5  e.con 16  min  8        (B  )  28  0.9  75.25  1.7  42.94  140
0 
46.2
5 
49.96 
25  Thangam  42  m  46  Idio  16.
5 
2.2  e.con 15.8  nil  7        (B )  16  0.7  89.44  1.2  62.63  105
0 
75.8
4 
79 
26  Muruges   42  m  50  Idio  1.4  3.1  none  12.4  nil  6        (A )  20  0.8  85.06  0.9  84.9  190
0 
50  82.47 
27  Munusamy  40  m  60  Alc  1.2  3.7  e.con 13  nil  6        (A )  26  0.9  92.59  1  76.03  195
0 
60.7  92.59 
28  Latha  40  f  44  Idio  2.7  1.8  e.con 14  nil  9        (B )  38  1.2  43.28  1.8  40.31  110
0 
58  36.92 
29  Sankar  44  m  50  Alc  21.
6 
2.2  e.con 19.3  min  12      (C )  18  0.8  83.33  1.54  47.85  170
0 
53  78.21 
30  Gandhi  44  m  45  Alc  20.
6 
4.6  e.con 27.7  min  11       (C )  31  0.9  68.57  1.51  48.89  120
0 
55  50.93 
31  Selvam  40  m  52  HbsA
g 
0.8  3.3  none  13  nil   6       (A )  18  0.8  90.27  0.99  76.4  190
0 
50  82.47 
32  Muniyan  45  m  69  Alc  3.1  3.2  e.con 16  nil  9        (B )  34  0.8  113.8  1.4  53.07  210
0 
49.5  90.23 
33  Murugan  37  m  45  Alc  8.1  3  e.con 18  min  9       (B)  22  0.6  107.2  0.82  93.66  130
0 
55.8
2 
84 
34  Chellandi  54  m  46  Alc  5.8  4.3  e.con 14  nil  8       (B)  21  0.8  68.6  1.4  53.07  150
0 
46  59.9 
   
 
35  Ibrahim  42  m  70  Idio  1.3  3.6  none  13  nil  5       (A )  26  1  95.2  0.8  96.08  230
0 
65  103.8
2 
36  Narayan  58  m  54  Idio  2.7  3.2  e.con 18  nil  8       (B)  39  1  60  1.7  42.94  190
0 
52  68.6 
37  Kuppan  42  m  50  Alc  3  3.5  none  14  nil  7       (B)  26  1  68.06  1.2  62.63  190
0 
52  68.6 
38  Mari  40  m  56  Alc  3.3  3.3  p.co
n 
12  min  11     (C )  40  1.2  64.81  1.8  40.31  120
0 
54.5  37.85 
39  Sudalai  57  m  66  Idio  7.5  3.3  p.co
n 
18  min  10     (C )  40  1.2  63.4  1.74  41.85  100
0 
55  31.83 
40  Arumuga        58  m  60  Alc  2.8  3.3  e.con 15  min  8       ( B)  34  1.1  62.12  1.8  40.31  990  83.7  52.29 
41  Subbu  56  f  50  Alc  8  2.2  e.con 12  nil  10      (C )  39  1.1  45.05  2.56  27.06  120
0 
58.0
8 
44 
42  Sakthivel  35  m  44  Idio  2.2  3.2  none  13  nil  7        (B)  54  0.9  71.29  1  76.03  110
0 
79  67 
43  Ravi  40  m  54  Alc  25.
5 
3  e.con 18  min  9        (B)  18  0.8  98.9  1.23  60.97  190
0 
54  89.06 
44  Madhava      47  m  50  Alc  2.8  2  e.con 18  min  9        (B)  15  0.7  92.26  0.84  89.11  105
0 
75  77 
45  Muruges  40  m  48  HbsA
g 
6  4  none  12  nil  7        (B)  24  0.6  111.11  0.82  93.66  130
0 
55  84 
46  Selvi  56  f  50  HbsA
g 
6.2  2.3  e.con 14  nil  10      (C )  29  1.1  45.07  1.8  40.31  120
0 
58.0
8 
44 
47  Raja  38  m  49  HbsA
g 
1.2  4  e.con 12  nil  6        (A)  18  0.8  86.77  0.9  76  170
0 
53  77 
48  Selvam  37  m  45  Wil  4  3.4  e.con 17  nil  9        (B)  30  0.8  107.22  1  76.03  130
0 
55  84 
49  Isakki  24  m  34  Alc  1.8  3.1  e.con 20  min  10      (C  )  20  1.2  45.55  2.6  26.58  400  48  11.11 
50  Kandasam
y 
58  m  42  Alc  1  3  e.con 15  nil  7          (B)  24  1.2  39.86  3.1  21.56  800  50  23.15 
 
Alc‐alcohol,  AI‐ autoimmune, idio‐idiopathic, sr.br‐serum bilirubin, sr.alb‐serum albumin, asc‐ascites, e.con‐ easily controlled, p.con‐poorly controlled, h.enc‐hepatic 
encephalopathy, min‐minimal, adv‐advanced. PT‐prothrombin time, bl.ur‐blood  urea, sr.cr‐serum creatinine, Egfr‐estimated  GFR, CGF‐ockcroft gault formula,  s.cys‐serum 
cystatin,  mea.gfr‐ measured  GFR.  
